| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. | Bioorg Med Chem Lett | 2001 | 2.86 |
| 2 | Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. | Br J Cancer | 2003 | 1.23 |
| 3 | Phenylethylaminergic mechanisms in attention-deficit disorder. | Biol Psychiatry | 1991 | 0.83 |
| 4 | Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. | Br J Cancer | 2008 | 0.78 |